Terpenoids as potential anti-alzheimer's disease therapeutics

Molecules

Volumn 17, Issue 3, 2012, Pages 3524-3538

  Yoo, Ki Yeol ^a   Park, So Young ^a  

^a Dankook University   (South Korea)

Author keywords

Alzheimer's disease; Terpenoids; Therapeutics

Indexed keywords

GINSENOSIDE; TERPENE;

ALZHEIMER DISEASE; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; HUMAN; REVIEW;

ALZHEIMER DISEASE; ANIMALS; GINSENOSIDES; HUMANS; MOLECULAR STRUCTURE; TERPENES;

EID: 84858980217     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules17033524     Document Type: Review

References (88)

1. Hebert, L. E.; Scherr, P. A.; Bienias, J. L.; Bennett, D. A.; Evans, D. A. Alzheimer disease in the US population: Prevalence estimates using the 2000 census. Arch. Neurol. 2003, 60, 1119-1122. (Pubitemid 36975801)
2. Selkoe, D. J. The cell biology of beta-amyloid precursor protein and presenilin in Alzheimer's disease. Trends Cell. Biol. 1998, 8, 447-453.
3. Selkoe, D. J. Alzheimer's disease: Genes, proteins, and therapy. Physiol. Rev. 2001, 81, 741-766. (Pubitemid 32267077)
4. Tanzi, R. E.; Bertram, L. Twenty years of the Alzheimer's disease amyloid hypothesis: A genetic perspective. Cell 2005, 120, 545-555. (Pubitemid 40269768)
5. Walsh, D. M.; Selkoe, D. J. A beta oligomers - a decade of discovery. J. Neurochem. 2007, 101, 1172-1184.
6. Kawahara, M.; Kuroda, Y. Molecular mechanism of neurodegeneration induced by Alzheimer's beta-amyloid protein: Channel formation and disruption of calcium homeostasis. Brain Res. Bull. 2000, 53, 389-397. (Pubitemid 32000815)
7. Lue, L. F.; Kuo, Y. M.; Roher, A. E.; Brachova, L.; Shen, Y.; Sue, L.; Beach, T.; Kurth, J. H.; Rydel, R. E.; Rogers, J. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am. J. Pathol. 1999, 155, 853-862. (Pubitemid 29426831)
8. Roberson, E. D.; Mucke, L. 100 years and counting: Prospects for defeating Alzheimer's disease. Science 2006, 314, 781-784. (Pubitemid 44706637)
9. Heneka, M. T.; O'Banion, M. K. Inflammatory processes in Alzheimer's disease. J. Neuroimmunol. 2007, 184, 69-91. (Pubitemid 46365992)
10. Yamamoto, N.; Matsubara, E.; Maeda, S.; Minagawa, H.; Takashima, A.; Maruyama, W.; Michikawa, M.; Yanagisawa, K. A ganglioside-induced toxic soluble Abeta assembly. Its enhanced formation from Abeta bearing the Arctic mutation. J. Biol. Chem. 2007, 282, 2646-2655. (Pubitemid 47076773)
11. Coulson, E. J. Does the p75 neurotrophin receptor mediate Abeta-induced toxicity in Alzheimer's disease? J. Neurochem. 2006, 98, 654-660. (Pubitemid 44051267)
12. de Felice, F. G.; Velasco, P. T.; Lambert, M. P.; Viola, K.; Fernandez, S. J.; Ferreira, S. T.; Klein, W. L. Abeta oligomers induce neuronal oxidative stress through an N-methyl-D-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine. J. Biol. Chem. 2007, 282, 11590-11601. (Pubitemid 47100810)
13. Shankar, G. M.; Bloodgood, B. L.; Townsend, M.; Walsh, D. M.; Selkoe, D. J.; Sabatini, B. L. Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J. Neurosci. 2007, 27, 2866-2875. (Pubitemid 46438992)
14. Magdesian, M. H.; Carvalho, M. M.; Mendes, F. A.; Saraiva, L. M.; Juliano, M. A.; Juliano, L.; Garcia-Abreu, J.; Ferreira, S. T. Amyloid-beta binds to the extracellular cysteine-rich domain of Frizzled and inhibits Wnt/beta-catenin signaling. J. Biol. Chem. 2008, 283, 9359-9368.
15. Nimmrich, V.; Grimm, C.; Draguhn, A.; Barghorn, S.; Lehmann, A.; Schoemaker, H.; Hillen, H.; Gross, G.; Ebert, U.; Bruehl, C. Amyloid beta oligomers (A beta (1-42) globulomer) suppress spontaneous synaptic activity by inhibition of P/Q-type calcium currents. J. Neurosci. 2008, 28, 788-797. (Pubitemid 351159014)
16. Mezler, M.; Barghorn, S.; Schoemaker, H.; Gross, G.; Nimmrich, V. Abeta oligomer directly modulates P/Q-type calcium currents in Xenopus oocytes. Br. J. Pharmacol. 2012, 165, 1572-1583.
17. Kosik, K. S.; Joachim, C. L.; Selkoe, D. J. Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease. Proc. Natl. Acad. Sci. USA 1986, 83, 4044-4048. (Pubitemid 16062419)
18. Kondo, J.; Honda, T.; Mori, H.; Hamada, Y.; Miura, R.; Ogawara, M.; Ihara, Y. The carboxyl third of tau is tightly bound to paired helical filaments. Neuron 1988, 1, 827-834.
19. Iqbal, K.; Liu, F.; Gong, C. X.; Alonso Adel, C.; Grundke-Iqbal, I. Mechanisms of tau-induced neurodegeneration. Acta Neuropathol. 2009, 118, 53-69.
20. Wallin, A. K.; Blennow, K.; Andreasen, N.; Minthon, L. CSF biomarkers for Alzheimer's Disease: levels of beta-amyloid, tau, phosphorylated tau relate to clinical symptoms and survival. Dement. Geriatr. Cogn. Disord. 2006, 21, 131-138. (Pubitemid 43201321)
21. Busciglio, J.; Lorenzo, A.; Yeh, J.; Yankner, B. A. beta-amyloid fibrils induce tau phosphorylation and loss of microtubule binding. Neuron 1995, 14, 879-888.
22. Greenberg, S. M.; Kosik, K. S. Secreted beta-APP stimulates MAP kinase and phosphorylation of tau in neurons. Neurobiol. Aging 1995, 16, 403-407; discussion 407-408.
23. Takashima, A.; Honda, T.; Yasutake, K.; Michel, G.; Murayama, O.; Murayama, M.; Ishiguro, K.; Yamaguchi, H. Activation of tau protein kinase I/glycogen synthase kinase-3beta by amyloid beta peptide (25-35) enhances phosphorylation of tau in hippocampal neurons. Neurosci. Res. 1998, 31, 317-323. (Pubitemid 28446014)
24. Zheng, W. H.; Bastianetto, S.; Mennicken, F.; Ma, W.; Kar, S. Amyloid beta peptide induces tau phosphorylation and loss of cholinergic neurons in rat primary septal cultures. Neuroscience 2002, 115, 201-121.
25. Leschik, J.; Welzel, A.; Weissmann, C.; Eckert, A.; Brandt, R. Inverse and distinct modulation of tau-dependent neurodegeneration by presenilin 1 and amyloid-beta in cultured cortical neurons: Evidence that tau phosphorylation is the limiting factor in amyloid-beta-induced cell death. J. Neurochem. 2007, 101, 1303-1315. (Pubitemid 46718815)
26. Francis, P. T.; Palmer, A. M.; Sims, N. R.; Bowen, D. M.; Davison, A. N.; Esiri, M. M.; Neary, D.; Snowden, J. S.; Wilcock, G. K. Neurochemical studies of early-onset Alzheimer's disease. Possible influence on treatment. N. Engl. J. Med. 1985, 313, 7-11. (Pubitemid 15068737)
27. Lipton, S. A. Pathologically-activated therapeutics for neuroprotection: Mechanism of NMDA receptor block by memantine and S-nitrosylation. Curr. Drug Targets 2007, 8, 621-632. (Pubitemid 46785060)
28. Ferris, S.; Ihl, R.; Robert, P.; Winblad, B.; Gatz, G.; Tennigkeit, F.; Gauthier, S. Treatment effects of Memantine on language in moderate to severe Alzheimer's disease patients. Alzheimers Dement. 2009, 5, 369-374.
29. Mecocci, P.; Bladstrom, A.; Stender, K. Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: Post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies. Int. J. Geriatr. Psychiatry 2009, 24, 532-538.
30. Newman, D. J.; Cragg, G. M. Natural products as sources of new drugs over the last 25 years. J. Nat. Prod. 2007, 70, 461-477. (Pubitemid 46595760)
31. Wang, Y.; Huang, L. Q.; Tang, X. C.; Zhang, H. Y. Retrospect and prospect of active principles from Chinese herbs in the treatment of dementia. Acta Pharmacol. Sin. 2010, 31, 649-664.
32. Liu, Z. Q.; Luo, X. Y.; Liu, G. Z.; Chen, Y. P.; Wang, Z. C.; Sun, Y. X. In vitro study of the relationship between the structure of ginsenoside and its antioxidative or prooxidative activity in free radical induced hemolysis of human erythrocytes. J. Agric. Food Chem. 2003, 51, 2555-2558.
33. Yun, T. K.; Lee, Y. S.; Lee, Y. H.; Kim, S. I.; Yun, H. Y. Anticarcinogenic effect of Panax ginseng C. A. Meyer and identification of active compounds. J. Korean Med. Sci. 2001, 16, S6-S18.
34. Chen, F.; Eckman, E. A.; Eckman, C. B. Reductions in levels of the Alzheimer's amyloid beta peptide after oral administration of ginsenosides. FASEB J. 2006, 20, 1269-1271.
35. Yang, L.; Hao, J.; Zhang, J.; Xia, W.; Dong, X.; Hu, X.; Kong, F.; Cui, X. Ginsenoside Rg3 promotes beta-amyloid peptide degradation by enhancing gene expression of neprilysin. J. Pharm. Pharmacol. 2009, 61, 375-380.
36. Zhao, R.; McDaniel, W. F. Ginseng improves strategic learning by normal and brain-damaged rats. Neuroreport 1998, 9, 1619-1624. (Pubitemid 28264298)
37. Fang, F.; Chen, X.; Huang, T.; Luddy, J. S.; Yan, S. S. Multi-faced neuroprotective effects of Ginsenoside Rg1 in an Alzheimer mouse model. Biochim. Biophys. Acta 2012, 1822, 286-292.
38. Shi, Y. Q.; Huang, T. W.; Chen, L. M.; Pan, X. D.; Zhang, J.; Zhu, Y. G.; Chen, X. C. Ginsenoside Rg1 attenuates amyloid-beta content, regulates PKA/CREB activity, and improves cognitive performance in SAMP8 mice. J. Alzheimers Dis. 2010, 19, 977-989.
39. Liang, W.; Ge, S.; Yang, L.; Yang, M.; Ye, Z.; Yan, M.; Du, J.; Luo, Z. Ginsenosides Rb1 and Rg1 promote proliferation and expression of neurotrophic factors in primary Schwann cell cultures. Brain Res. 2010, 1357, 19-25.
40. Chen, L. M.; Lin, Z. Y.; Zhu, Y. G.; Lin, N.; Zhang, J.; Pan, X. D.; Chen, X. C. Ginsenoside Rg1 attenuates beta-amyloid generation via suppressing PPARgamma-regulated BACE1 activity in N2a-APP695 cells. Eur. J. Pharmacol. 2012, 675, 15-21.
41. Wang, Y.; Liu, J.; Zhang, Z.; Bi, P.; Qi, Z.; Zhang, C. Anti-neuroinflammation effect of ginsenoside Rbl in a rat model of Alzheimer disease. Neurosci. Lett. 2011, 487, 70-72.
42. Mook-Jung, I.; Hong, H. S.; Boo, J. H.; Lee, K. H.; Yun, S. H.; Cheong, M. Y.; Joo, I.; Huh, K.; Jung, M. W. Ginsenoside Rb1 and Rg1 improve spatial learning and increase hippocampal synaptophysin level in mice. J. Neurosci. Res. 2001, 63, 509-515. (Pubitemid 32193708)
43. Kennedy, D. O.; Scholey, A. B.; Wesnes, K. A. Dose dependent changes in cognitive performance and mood following acute administration of Ginseng to healthy young volunteers. Nutr. Neurosci. 2001, 4, 295-310. (Pubitemid 33130418)
44. Reay, J. L.; Scholey, A. B.; Kennedy, D. O. Panax ginseng (G115) improves aspects of working memory performance and subjective ratings of calmness in healthy young adults. Hum. Psychopharmacol. 2010, 25, 462-471.
45. Lee, S. T.; Chu, K.; Sim, J. Y.; Heo, J. H.; Kim, M. Panax ginseng enhances cognitive performance in Alzheimer disease. Alzheimer Dis. Assoc. Disord. 2008, 22, 222-226.
46. ® in cognitive disorders. Pharmacopsychiatry 2003, 36, 44-49.
47. Shi, C.; Zhao, L.; Zhu, B.; Li, Q.; Yew, D. T.; Yao, Z.; Xu, J. Protective effects of Ginkgo biloba extract (EGb761) and its constituents quercetin and ginkgolide B against beta-amyloid peptide-induced toxicity in SH-SY5Y cells. Chem. Biol. Interact. 2009, 181, 115-123.
48. Bate, C.; Tayebi, M.; Williams, A. Ginkgolides protect against amyloid-beta1-42-mediated synapse damage in vitro. Mol. Neurodegener. 2008, 3, 1.
49. Bate, C.; Salmona, M.; Williams, A. Ginkgolide B inhibits the neurotoxicity of prions or amyloid-beta1-42. J. Neuroinflammation 2004, 1, 4.
50. Xiao, Q.; Wang, C.; Li, J.; Hou, Q.; Ma, J.; Wang, W.; Wang, Z. Ginkgolide B protects hippocampal neurons from apoptosis induced by beta-amyloid 25-35 partly via up-regulation of brain-derived neurotrophic factor. Eur. J. Pharmacol. 2010, 647, 48-54.
51. Hu, Y. Y.; Huang, M.; Dong, X. Q.; Xu, Q. P.; Yu, W. H.; Zhang, Z. Y. Ginkgolide B reduces neuronal cell apoptosis in the hemorrhagic rat brain: Possible involvement of Toll-like receptor 4/nuclear factor-kappa B pathway. J. Ethnopharmacol. 2011, 137, 1462-1468.
52. Wu, Y.; Wu, Z.; Butko, P.; Christen, Y.; Lambert, M. P.; Klein, W. L.; Link, C. D.; Luo, Y. Amyloid-beta-induced pathological behaviors are suppressed by Ginkgo biloba extract EGb 761 and ginkgolides in transgenic Caenorhabditis elegans. J. Neurosci. 2006, 26, 13102-13113. (Pubitemid 44954628)
53. Lee, T. F.; Chen, C. F.; Wang, L. C. Effect of ginkgolides on beta-amyloid-suppressed acetylocholine release from rat hippocampal slices. Phytother. Res. 2004, 18, 556-560. (Pubitemid 39079153)
54. Vitolo, O.; Gong, B.; Cao, Z.; Ishii, H.; Jaracz, S.; Nakanishi, K.; Arancio, O.; Dzyuba, S. V.; Lefort, R.; Shelanski, M. Protection against beta-amyloid induced abnormal synaptic function and cell death by Ginkgolide J. Neurobiol. Aging 2009, 30, 257-265.
55. Tchantchou, F.; Lacor, P. N.; Cao, Z.; Lao, L.; Hou, Y.; Cui, C.; Klein, W. L.; Luo, Y. Stimulation of neurogenesis and synaptogenesis by bilobalide and quercetin via common final pathway in hippocampal neurons. J. Alzheimers Dis. 2009, 18, 787-798.
56. Ahlemeyer, B.; Mowes, A.; Krieglstein, J. Inhibition of serum deprivation-and staurosporine-induced neuronal apoptosis by Ginkgo biloba extract and some of its constituents. Eur. J. Pharmacol. 1999, 367, 423-430. (Pubitemid 29106397)
57. Defeudis, F. V. Bilobalide and neuroprotection. Pharmacol. Res. 2002, 46, 565-568. (Pubitemid 35439170)
58. Howlett, A. C.; Barth, F.; Bonner, T. I.; Cabral, G.; Casellas, P.; Devane, W. A.; Felder, C. C.; Herkenham, M.; Mackie, K.; Martin, B. R.; et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol. Rev. 2002, 54, 161-202. (Pubitemid 34575709)
59. Herkenham, M.; Lynn, A. B.; Little, M. D.; Johnson, M. R.; Melvin, L. S.; de Costa, B. R.; Rice, K. C. Cannabinoid receptor localization in brain. Proc. Natl. Acad. Sci. USA 1990, 87, 1932-1936.
60. Pertwee, R. G. Cannabinoid pharmacology: The first 66 years. Br. J. Pharmacol. 2006, 147, S163-S171. (Pubitemid 43077274)
61. Carlini, E. A. The good and the bad effects of (-) trans-delta-9- tetrahydrocannabinol (Delta 9-THC) on humans. Toxicon 2004, 44, 461-467. (Pubitemid 39070645)
62. Eubanks, L. M.; Rogers, C. J.; Beuscher, A. E., IV; Koob, G. F.; Olson, A. J.; Dickerson, T. J.; Janda, K. D. A molecular link between the active component of marijuana and Alzheimer's disease pathology. Mol. Pharm. 2006, 3, 773-777. (Pubitemid 46087493)
63. Walther, S.; Mahlberg, R.; Eichmann, U.; Kunz, D. Delta-9- tetrahydrocannabinol for nighttime agitation in severe dementia. Psychopharmacology (Berl) 2006, 185, 524-528.
64. Hampson, A. J.; Grimaldi, M.; Axelrod, J.; Wink, D. Cannabidiol and (-) Delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proc. Natl. Acad. Sci. USA 1998, 95, 8268-8273. (Pubitemid 28326102)
65. Iuvone, T.; Esposito, G.; Esposito, R.; Santamaria, R.; di Rosa, M.; Izzo, A. A. Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on beta-amyloid-induced toxicity in PC12 cells. J. Neurochem. 2004, 89, 134-141. (Pubitemid 38420682)
66. Esposito, G.; de Filippis, D.; Maiuri, M. C.; de Stefano, D.; Carnuccio, R.; Iuvone, T. Cannabidiol inhibits inducible nitric oxide synthase protein expression and nitric oxide production in beta-amyloid stimulated PC12 neurons through p38 MAP kinase and NF-kappaB involvement. Neurosci. Lett. 2006, 399, 91-95.
67. Esposito, G.; de Filippis, D.; Carnuccio, R.; Izzo, A. A.; Iuvone, T. The marijuana component cannabidiol inhibits beta-amyloid-induced tau protein hyperphosphorylation through Wnt/beta-catenin pathway rescue in PC12 cells. J. Mol. Med. (Berl) 2006, 84, 253-258. (Pubitemid 43291014)
68. Esposito, G.; Scuderi, C.; Savani, C.; Steardo, L., Jr.; de Filippis, D.; Cottone, P.; Iuvone, T.; Cuomo, V.; Steardo, L. Cannabidiol in vivo blunts beta-amyloid induced neuroinflammation by suppressing IL-1beta and iNOS expression. Br. J. Pharmacol. 2007, 151, 1272-1279. (Pubitemid 47255904)
69. Martin-Moreno, A. M.; Reigada, D.; Ramirez, B. G.; Mechoulam, R.; Innamorato, N.; Cuadrado, A.; de Ceballos, M. L. Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: Relevance to Alzheimer's disease. Mol. Pharmacol. 2011, 79, 964-973.
70. Ramirez, B. G.; Blazquez, C.; Gomez del Pulgar, T.; Guzman, M.; de Ceballos, M. L. Prevention of Alzheimer's disease pathology by cannabinoids: Neuroprotection mediated by blockade of microglial activation. J. Neurosci. 2005, 25, 1904-1913. (Pubitemid 40289395)
71. Martin Moreno, A. M.; Brera, B.; Spuch, C.; Carro, E.; Garcia-Garcia, L.; Delgado, M.; Pozo, M. A.; Innamorato, N. G.; Cuadrado, A.; de Ceballos, M. L. Prolonged oral cannabinoid administration prevents neuroinflammation, lowers beta-amyloid levels and improves cognitive performance in Tg APP 2576 mice. J. Neuroinflamm. 2012, 9, 8.
72. Li, C. Y.; Li, L.; Li, Y. H.; Ai, H. X.; Zhang, L. Effects of extract from Cornus officinalis on nitric oxide and NF-kappaB in cortex of cerebral infarction rat model. Zhongguo Zhong Yao Za Zhi 2005, 30, 1667-1670. (Pubitemid 44795735)
73. Zhao, L. H.; Ding, Y. X.; Zhang, L.; Li, L. Cornel iridoid glycoside improves memory ability and promotes neuronal survival in fimbria-fornix transected rats. Eur. J. Pharmacol. 2010, 647, 68-74.
74. Cho, S. O.; Ban, J. Y.; Kim, J. Y.; Jeong, H. Y.; Lee, I. S.; Song, K. S.; Bae, K.; Seong, Y. H. Aralia cordata protects against amyloid beta protein (25-35)-induced neurotoxicity in cultured neurons and has antidementia activities in mice. J. Pharmacol. Sci. 2009, 111, 22-32.
75. Cho, S. O.; Ban, J. Y.; Kim, J. Y.; Ju, H. S.; Lee, I. S.; Song, K. S.; Bae, K.; Seong, Y. H. Anti-ischemic activities of aralia cordata and its active component, oleanolic acid. Arch. Pharm. Res. 2009, 32, 923-932.
76. Jia, H.; Jiang, Y.; Ruan, Y.; Zhang, Y.; Ma, X.; Zhang, J.; Beyreuther, K.; Tu, P.; Zhang, D. Tenuigenin treatment decreases secretion of the Alzheimer's disease amyloid beta-protein in cultured cells. Neurosci. Lett. 2004, 367, 123-128. (Pubitemid 39078799)
77. Lv, J.; Jia, H.; Jiang, Y.; Ruan, Y.; Liu, Z.; Yue, W.; Beyreuther, K.; Tu, P.; Zhang, D. Tenuifolin, an extract derived from tenuigenin, inhibits amyloid-beta secretion in vitro. Acta Physiol. (Oxf) 2009, 196, 419-425.
78. Zhang, H.; Han, T.; Zhang, L.; Yu, C. H.; Wan, D. G.; Rahman, K.; Qin, L. P.; Peng, C. Effects of tenuifolin extracted from radix polygalae on learning and memory: A behavioral and biochemical study on aged and amnesic mice. Phytomedicine 2008, 15, 587-594.
79. Kim, S. Y.; Moon, T. C.; Chang, H. W.; Son, K. H.; Kang, S. S.; Kim, H. P. Effects of tanshinone I isolated from Salvia miltiorrhiza bunge on arachidonic acid metabolism and in vivo inflammatory responses. Phytother. Res. 2002, 16, 616-620. (Pubitemid 35334180)
80. Ng, T. B.; Liu, F.; Wang, Z. T. Antioxidative activity of natural products from plants. Life Sci. 2000, 66, 709-723. (Pubitemid 30077864)
81. Park, E. J.; Zhao, Y. Z.; Kim, Y. C.; Sohn, D. H. PF2401-SF, standardized fraction of Salvia miltiorrhiza and its constituents, tanshinone I, tanshinone IIA, and cryptotanshinone, protect primary cultured rat hepatocytes from bile acid-induced apoptosis by inhibiting JNK phosphorylation. Food Chem. Toxicol. 2007, 45, 1891-1898. (Pubitemid 47238203)
82. Kim, D. H.; Jeon, S. J.; Jung, J. W.; Lee, S.; Yoon, B. H.; Shin, B. Y.; Son, K. H.; Cheong, J. H.; Kim, Y. S.; Kang, S. S.; et al. Tanshinone congeners improve memory impairments induced by scopolamine on passive avoidance tasks in mice. Eur. J. Pharmacol. 2007, 574, 140-147. (Pubitemid 47592846)
83. Mei, Z.; Zhang, F.; Tao, L.; Zheng, W.; Cao, Y.; Wang, Z.; Tang, S.; Le, K.; Chen, S.; Pi, R.; et al. Cryptotanshinone, a compound from Salvia miltiorrhiza modulates amyloid precursor protein metabolism and attenuates beta-amyloid deposition through upregulating alpha-secretase in vivo and in vitro. Neurosci. Lett. 2009, 452, 90-95.
84. Mei, Z.; Situ, B.; Tan, X.; Zheng, S.; Zhang, F.; Yan, P.; Liu, P. Cryptotanshinione upregulates alpha-secretase by activation PI3K pathway in cortical neurons. Brain Res. 2010, 1348, 165-173.
85. Mei, Z.; Yan, P.; Situ, B.; Mou, Y.; Liu, P. Cryptotanshinione inhibits beta-amyloid aggregation and protects damage from beta-amyloid in SH-SY5Y cells. Neurochem. Res. 2012, 37, 622-628.
86. Chung, Y. K.; Heo, H. J.; Kim, E. K.; Kim, H. K.; Huh, T. L.; Lim, Y.; Kim, S. K.; Shin, D. H. Inhibitory effect of ursolic acid purified from Origanum majorana L on the acetylcholinesterase. Mol. Cells 2001, 11, 137-143. (Pubitemid 33663351)
87. Heo, H. J.; Cho, H. Y.; Hong, B.; Kim, H. K.; Heo, T. R.; Kim, E. K.; Kim, S. K.; Kim, C. J.; Shin, D. H. Ursolic acid of Origanum majorana L. reduces Abeta-induced oxidative injury. Mol. Cells 2002, 13, 5-11. (Pubitemid 41583042)
88. Wilkinson, K.; Boyd, J. D.; Glicksman, M.; Moore, K. J.; El Khoury, J. A high content drug screen identifies ursolic acid as an inhibitor of amyloid beta protein interactions with its receptor CD36. J. Biol. Chem. 2011, 286, 34914-34922.